Insights

Unique Biotech Innovation Climb Bio is developing a novel anti-APRIL monoclonal antibody, CLYM116, which presents an opportunity for sales teams to target the specific needs of patients with immune-mediated diseases that are not adequately addressed by existing therapies.

Financially Strong With a recent financing of $210 million and a stable cash reserve, Climb Bio is financially healthy and well-positioned to invest in research and development, making them a potential long-term partner for sales collaborations and product distribution agreements.

Experienced Leadership The appointment of Douglas E. Williams, Ph.D., as the Chair of Board of Directors brings valuable expertise to Climb Bio. Leveraging Dr. Williams' leadership, sales teams can explore strategic partnerships and alliances that capitalize on his industry network and experience.

Participation in Key Conferences Climb Bio's active participation in prestigious events like the Oppenheimer 35th Annual Healthcare Life Sciences Conference opens doors for sales professionals to engage with key stakeholders, present products, and forge partnerships that can drive revenue growth.

Market Growth Potential Amid a rising global prevalence of immune-mediated diseases, Climb Bio's focus on impacting disease pathways indicates a promising market potential. Sales teams can capitalize on this growing demand by offering innovative solutions tailored to unmet clinical needs.

Climb Bio Tech Stack

Climb Bio uses 8 technology products and services including Google Analytics, Cloudflare, WordPress, and more. Explore Climb Bio's tech stack below.

  • Google Analytics
    Analytics
  • Cloudflare
    Content Management System
  • WordPress
    Content Management System
  • jQuery
    Javascript Libraries
  • WP Engine
    Platform As A Service
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • Tailwind CSS
    UI Frameworks

Climb Bio's Email Address Formats

Climb Bio uses at least 2 format(s):
Climb Bio Email FormatsExamplePercentage
First.Last@eliemtx.comJohn.Doe@eliemtx.com
100%

Frequently Asked Questions

Where is Climb Bio's headquarters located?

Minus sign iconPlus sign icon
Climb Bio's main headquarters is located at Wellesley, MA 02481 US. The company has employees across 2 continents, including North AmericaEurope.

What is Climb Bio's stock symbol?

Minus sign iconPlus sign icon
Climb Bio is a publicly traded company; the company's stock symbol is CLYM.

What is Climb Bio's official website and social media links?

Minus sign iconPlus sign icon
Climb Bio's official website is climbbio.com and has social profiles on LinkedIn.

How much revenue does Climb Bio generate?

Minus sign iconPlus sign icon
As of January 2025, Climb Bio's annual revenue reached $1.8M.

What is Climb Bio's SIC code NAICS code?

Minus sign iconPlus sign icon
Climb Bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Climb Bio have currently?

Minus sign iconPlus sign icon
As of January 2025, Climb Bio has approximately 20 employees across 2 continents, including North AmericaEurope. Key team members include Chief Operating Officer: B. K.Chief Operating Officer And Chief Financial Officer: E. L.Vice President Of Clinical Development: R. O.. Explore Climb Bio's employee directory with LeadIQ.

What industry does Climb Bio belong to?

Minus sign iconPlus sign icon
Climb Bio operates in the Biotechnology Research industry.

What technology does Climb Bio use?

Minus sign iconPlus sign icon
Climb Bio's tech stack includes Google AnalyticsCloudflareWordPressjQueryWP EnginePHPYoast SEOTailwind CSS.

What is Climb Bio's email format?

Minus sign iconPlus sign icon
Climb Bio's email format typically follows the pattern of . Find more Climb Bio email formats with LeadIQ.

When was Climb Bio founded?

Minus sign iconPlus sign icon
Climb Bio was founded in 2018.
Climb Bio

Climb Bio

Biotechnology ResearchMassachusetts, United States11-50 Employees

Immune-mediated diseases impact 1:7 people and are increasing in prevalence worldwide. They occur when the immune system mistakenly attacks the tissues of the body and can result in permanent organ damage or even death. Despite advances in treatment, many patients with immune-mediated diseases suffer from poor outcomes when their disease cannot be controlled with available therapies. At Climb Bio, we believe that we can impact the pathways that cause immune-mediated diseases to give patients precious time free of disease.

Section iconCompany Overview

Headquarters
Wellesley, MA 02481 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CLYM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $10M

    Climb Bio's revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    Climb Bio's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.